Zur Rose Group via its subsidiary Zur Rose Finance successfully completed the placement of senior unsecured bonds due 2025 guaranteed by the company and convertible into registered shares of the company. The nominal amount of the issuance has been increased by CHF 25 million to a total size of CHF 175 million, following a strong demand. The proceeds will be used, among others, to rapidly adjust to the significantly increased levels of demand for vital medication offered by online pharmacies since the beginning of the COVID-19 crisis. Merrill Lynch International and UBS acted as joint global coordinators and joint bookrunners in this transaction.
A cross-border team of Baker McKenzie are acting as legal counsel to Zur Rose Group in this operation. The team was led by partner Matthias Courvoisier (Zurich) and included Adam Farlow (partner, London), Yves Mauchle (senior associate, Zurich), Philip Spoerlé (senior associate, Zurich), Beau Visser (associate, Zurich), Thijs Bogaers (associate, Amsterdam), Vera van Blerck (associate, Amsterdam), Tim Alferink (partner, Amsterdam), Philippe Steffens (partner, Amsterdam), Jorien Reestman (associate, Amsterdam), Andrea Bolliger (counsel, Zurich), Ariane Ernst (associate, Zurich).